SEC Form 4 · accession 0001209191-18-062266
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander O. Schuth
Officer — COO and Secretary
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 5:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3,F4 | Dec 10, 2018 | S | 2,500 | $20.18 | D | 682,589 | I | See footnote |
| Common StockF5,F4 | Dec 11, 2018 | S | 2,500 | $20.22 | D | 680,089 | I | See footnote |
| Common StockF6,F4 | Dec 12, 2018 | S | 2,500 | $20.80 | D | 677,589 | I | See footnote |
| Common StockF1 | holding | — | — | — | 15,738 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 1,802 shares acquired on May 31, 2018 and 975 shares acquired on November 30, 2018 under the Issuer's 2017 Employee Stock Purchase Plan.
- F2The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F3The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.74 to $20.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F4The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee.
- F5The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.90 to $20.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F6The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.51 to $20.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.